Many of us are looking forward to the progress. You should have Mr. Goett contact HRCT's leadership. Particularly if Mr. Goett is getting interest in China. These two could REALLY hit it big!
Peace. . .
Keep the Faith!
M&M Man
Recent JANX News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/08/2024 09:47:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/08/2024 09:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:11:29 PM
- Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights • Business Wire • 03/08/2024 09:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/29/2024 10:30:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 10:11:11 PM
- Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants • Business Wire • 02/29/2024 06:22:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 02/29/2024 02:55:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 10:15:06 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/28/2024 02:50:39 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 10:23:20 PM
- Janux Therapeutics Announces Proposed Public Offering of Common Stock • Business Wire • 02/27/2024 10:00:00 PM
- Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors • Business Wire • 02/26/2024 09:05:00 PM
- Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 • Business Wire • 02/20/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 09:31:05 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/01/2024 09:15:27 PM
- Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer • Business Wire • 01/08/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:54:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:53:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:50:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:49:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:47:56 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:45:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 09:19:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:07:54 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM